252 related articles for article (PubMed ID: 11970768)
1. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
Leopold LH; Berger MS; Feingold J
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
[TBL] [Abstract][Full Text] [Related]
3. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
4. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
5. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
[TBL] [Abstract][Full Text] [Related]
6. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
[TBL] [Abstract][Full Text] [Related]
7. Current use and future development of gemtuzumab ozogamicin.
Larson RA
Semin Hematol; 2001 Jul; 38(3 Suppl 6):24-31. PubMed ID: 11474494
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
11. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
Larson RA; Boogaerts M; Estey E; Karanes C; Stadtmauer EA; Sievers EL; Mineur P; Bennett JM; Berger MS; Eten CB; Munteanu M; Loken MR; Van Dongen JJ; Bernstein ID; Appelbaum FR;
Leukemia; 2002 Sep; 16(9):1627-36. PubMed ID: 12200674
[TBL] [Abstract][Full Text] [Related]
12. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
Molnár I; Powell BL
Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
[TBL] [Abstract][Full Text] [Related]
13. Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia.
Nabhan C; Tallman MS
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S19-23. PubMed ID: 11970766
[TBL] [Abstract][Full Text] [Related]
14. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Giles FJ; Kantarjian HM; Kornblau SM; Thomas DA; Garcia-Manero G; Waddelow TA; David CL; Phan AT; Colburn DE; Rashid A; Estey EH
Cancer; 2001 Jul; 92(2):406-13. PubMed ID: 11466696
[TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
16. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.
Parigger J; Zwaan CM; Reinhardt D; Kaspers GJ
Expert Rev Anticancer Ther; 2016; 16(2):137-46. PubMed ID: 26646091
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin.
McGavin JK; Spencer CM
Drugs; 2001; 61(9):1317-22; discussion 1323-4. PubMed ID: 11511025
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
[TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab ozogamicin (GO) in relapsed/refractory patients with acute myeloid leukemia.
Yamaguchi Y; Usui N; Dobashi N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Ogasawara Y; Saito T; Minami J; Kobayashi T; Katsube A; Kamiyama Y; Machishima T; Morikawa N; Otsubo H; Kaito K; Asai O; Aiba K
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1105-9. PubMed ID: 19620797
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Stadtmauer EA
Curr Oncol Rep; 2002 Sep; 4(5):375-80. PubMed ID: 12162910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
